首页> 外文OA文献 >Phase 3 randomised study of daratumumab, bortezomib and dexamethasone (DVd) vs bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR

【2h】

Phase 3 randomised study of daratumumab, bortezomib and dexamethasone (DVd) vs bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR

机译：患者（PTS）中达拉姆宫，硼替佐米和地塞米松（DVD）和硼替米布（DVD）和地塞米松（VD）的第3阶段随机研究，复发或难治多骨髓瘤（RRMM）：蓖麻

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
K. Weisel; A. Palumbo; A. Chanan-Khan; A.K. Nooka; I. Spicka; T. Masszi; M. Beksac; V. Hungria; M. Munder; M.-V. Mateos; T.M. Mark; A. Spencer; M. Qi; J. Schecter; H. Amin; X. Qin; W. Deraedt; T. Ahmadi; P. Sonneveld;
展开▼
作者单位

展开▼
年度 2016
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
专利

1. Evaluation of Sustained Minimal Residual Disease (MRD) Negativity in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated with Daratumumab in Combination with Lenalidomide Plus Dexamethasone (D-Rd) or Bortezomib Plus Dexamethasone (D-Vd): Analysis of Pollux and Castor [J] . Avet-Loiseau Herve, San-Miguel Jesus F., Casneuf Tineke, Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：用达拉姆珠三任骨（RRMM）与Lenalalomide Plus地塞米松（D-Rd）或Bortezomib加上地塞米松（D-VD）组合治疗的复发/难治性多发性疾病（RRMM）患者（RRMM）患者（RRMM）患者（RRMM）患者（RRMM）患者（RRMM）患者（PTS）的评估持续最小的和脚轮
2. ANCHOR (OP-104) Study of Melflufen and Dexamethasone Plus Bortezomib or Daratumumab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to an IMiD and/or a Proteasome Inhibitor (PI): Phase 1 Update [J] . Pour Ludek, Efebera Yvonne A., Granell Miquel, Clinical lymphoma, myeloma & leukemia . 2019,第Suppla1期

机译：锚（OP-104）对Melflufen和Dexamethasone的研究与含有复发/难治多骨髓瘤（RRMM）难以解决的患者（RRMM）难以解决含有IMID和/或蛋白酶体抑制剂（PI）：第1阶段更新
3. Evaluation of Minimal Residual Disease (MRD) in Relapsed/Refractory Multiple Myeloma (RRMM) Patients Treated with Daratumumab in Combination with Lenalidomide Plus Dexamethasone or Bortezomib Plus Dexamethasone [J] . Avet-Loiseau Herve, Casneuf Tineke, Chiu Christopher, Blood: The Journal of the American Society of Hematology . 2016,第22期

机译：达那妥单抗联合来那度胺联合地塞米松或硼替佐米联合地塞米松治疗的复发/难治性多发性骨髓瘤（RRMM）患者的最低残留疾病（MRD）评估
4. Proteomic alterations caused by treatment with Bortezomib, Doxorubicin, and Dexamethasone in Myeloma [C] . Dominik Dytfeld, Vadiraja B. Bhat, Malathi Hari, American Society for Mass Spectrometry Conference on Mass Spectrometry and Allied Topics . 2009

机译：用髓质族，多柔比星和地塞米松治疗引起的蛋白质组学改变
5. A Phase 1/2 Study of Ixazomib as a Replacement for Bortezomib or Carfilzomib for Multiple Myeloma Patients Recently Relapsed or Refractory to Their Last Combination Regimen Containing Either Bortezomib or Carfilzomib [D] . Forouzan, Eli. 2020

机译：Ixazomib的第1/2期作为替代品髓鞘或胭脂瘤患者的替代品的替代物，最近对含有Bortezomib或Carfilzomib的最后组合方案复发或难治
6. Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR [O] . Andrew Spencer, Suzanne Lentzsch, Katja Weisel, 2018

机译：复发性或难治性多发性骨髓瘤中Daratumumab加硼替佐米和地塞米松与硼替佐米和地塞米松的比较：CASTOR的最新分析
7. DARATUMUMAB, BORTEZOMIB AND DEXAMETHASONE (DVD) VS BORTEZOMIB AND DEXAMETHASONE (VD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): EFFICACY AND SAFETY UPDATE (CASTOR) [O] . S. Lentzsch, K. Weisel, M.V. Mateos, 2017

机译：Daratumumab，Bortezomib和地塞米松（DVD）与Bortezomib和DexameLasone（VD）复发或难治多骨髓瘤（RRMM）：功效和安全更新（蓖麻）

Phase 3 randomised study of daratumumab, bortezomib and dexamethasone (DVd) vs bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR

著录项

相似文献

相关主题

期刊订阅